Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study

被引：24
|
作者：
Matulonis, Ursula A.
Shapira-Frommer, Ronnie
Santin, Alessandro
Lisyanskaya, Alla Sergeevua
Pignata, Sandro
Vergote, Ignace
Raspagliesi, Francesco
Sonke, Gabe S.
Birrer, Michael
Provencher, Diane M.
Sehouli, Jalid
Colombo, Nicoletta
Gonzalez-Martin, Antonio
Oaknin, Ana
Ottevanger, P. B.
Rudaitis, Vilius
Katchar, Kia
Wang, Zhen
Ruman, Jane
Ledermann, Jonathan A.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Sheba Med Ctr, Ramat Gan, Israel
[3] Yale Univ, Sch Med, New Haven, CT USA
[4] St Petersburg City Oncol Hosp, St Petersburg, Russia
[5] NCI Naples, Naples, Italy
[6] Univ Hosp Leuven, Leuven, Belgium
[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[8] Netherlands Canc Inst, Amsterdam, Netherlands
[9] BOOG Study Ctr, Amsterdam, Netherlands
[10] Univ Alabama Birmingham, Birmingham, AL USA
[11] Ctr Hosp Univ Montreal CHUM, Montreal, PQ, Canada
[12] Charite Med Univ Berlin, Berlin, Germany
[13] Univ Milano Bicocca, Milan, Italy
[14] European Inst Oncol, Milan, Italy
[15] Clin Univ Navarra, MD Anderson Int Espana, Madrid, Spain
[16] Vall Hebron Inst Oncol VHIO, Barcelona, Spain
[17] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
[18] Vilnius Univ, Inst Clin Med, Vilnius, Lithuania
[19] Merck Co Inc, Kenilworth, NJ USA
[20] UCL, Canc Inst, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5511
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
    Matulonis, U. A.
    Shapira-Frommer, R.
    Santin, A. D.
    Lisyanskaya, A. S.
    Pignata, S.
    Vergote, I
    Raspagliesi, F.
    Sonke, G. S.
    Birrer, M.
    Provencher, D. M.
    Sehouli, J.
    Colombo, N.
    Gonzalez-Martin, A.
    Oaknin, A.
    Ottevanger, P. B.
    Rudaitis, V
    Katchar, K.
    Wu, H.
    Keefe, S.
    Ruman, J.
    Ledermann, J. A.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1080 - 1087
  • [2] KEYNOTE-100: Phase 2 trial of pembrolizumab in patients with advanced recurrent ovarian cancer
    Matulonis, U. A.
    Chen, M.
    Puhlmann, M.
    Shentu, Y.
    Ledermann, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.
    Matulonis, Ursula A.
    Shapira, Roni
    Santin, Alessandro
    Lisyanskaya, Alla Sergeevna
    Pignata, Sandro
    Vergote, Ignace
    Raspagliesi, Francesco
    Sonke, Gabe S.
    Birrer, Michael
    Sehouli, Jalid
    Colombo, Nicoletta
    Gonzalez-Martin, Antonio
    Oaknin, Ana
    Ottevanger, P. B.
    Rudaitis, Vilius
    Wu, Haiyan
    Keefe, Stephen Michael
    Stein, Karen
    Ledermann, Jonathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100
    Nishio, Shin
    Matsumoto, Koji
    Takehara, Kazuhiro
    Kawamura, Naoki
    Hasegawa, Kosei
    Takeshima, Nobuhiro
    Aoki, Daisuke
    Kamiura, Shoji
    Arakawa, Atsushi
    Kondo, Eiji
    Hirakawa, Tomoko
    Yamamoto, Keiko
    Aoki, Masayuki
    Stein, Karen
    Keefe, Stephen
    Fujiwara, Keiichi
    Ushijima, Kimio
    CANCER SCIENCE, 2020, 111 (04) : 1324 - 1332
  • [5] Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study
    Ledermann, J. A.
    Shapira-Frommer, R.
    Santin, A.
    Lisyanskaya, A. S.
    Pignata, S.
    Vergote, I.
    Raspagliesi, F.
    Sonke, G. S.
    Birrer, M. J.
    Provencher, D. M.
    Sehouli, J.
    Colombo, N.
    Gonzalez-Martin, A.
    Oaknin, A.
    Ottevanger, P. B.
    Rudaitis, V.
    Cristescu, R.
    Kobie, J.
    Ruman, J.
    Matulonis, U. A.
    ANNALS OF ONCOLOGY, 2018, 29 : 728 - 728
  • [6] Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
    Ledermann, Jonathan A.
    Shapira-Frommer, Ronnie
    Santin, Alessandro D.
    Lisyanskaya, Alla S.
    Pignata, Sandro
    Vergote, Ignace
    Raspagliesi, Francesco
    Sonke, Gabe S.
    Birrer, Michael
    Provencher, Diane M.
    Sehouli, Jalid
    Colombo, Nicoletta
    Gonzalez-Martin, Antonio
    Oaknin, Ana
    Ottevanger, P. B.
    Rudaitis, Vilius
    Kobie, Julie
    Nebozhyn, Michael
    Edmondson, Mackenzie
    Sun, Yuan
    Cristescu, Razvan
    Jelinic, Petar
    Keefe, Stephen M.
    Matulonis, Ursula A.
    GYNECOLOGIC ONCOLOGY, 2023, 178 : 119 - 129
  • [7] Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.
    Varga, Andrea
    Piha-Paul, Sarina Anne
    Ott, Patrick Alexander
    Mehnert, Janice M.
    Berton-Rigaud, Dominique
    Johnson, Elizabeth A.
    Cheng, Jonathan D.
    Yuan, Sammy
    Rubin, Eric H.
    Matei, Daniela E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100
    Ledermann, J. A.
    Shapira-Frommer, R.
    Santin, A. D.
    Lisyanskaya, A.
    Pignata, S.
    Vergote, I. B.
    Raspagliesi, F.
    Sonke, G. S.
    Birrer, M.
    Provencher, D.
    Sehouli, J.
    Colombo, N.
    Gonzalez Martin, A.
    Oaknin, A.
    Saadatpour, A.
    Kobie, J.
    Jelinic, P.
    Stein, K.
    Matulonis, U. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S631 - S632
  • [9] KN100: Results from Japanese patients with advanced recurrent ovarian cancer treated with pembrolizumab monotherapy
    Matsumoto, Koji
    Nishio, Shin
    Takehara, Kazuhiro
    Kawamura, Naoki
    Hasegawa, Kosei
    Takeshima, Nobuhiro
    Aoki, Daisuke
    Kamiura, Shoji
    Arakawa, Atsushi
    Kondo, Eiji
    Hirakawa, Tomoko
    Yamamoto, Keiko
    Han, Shi Rong
    Stein, Karen
    Keefe, Stephen
    Lederman, Jonathan
    Matulonis, Ursula
    Fujiwara, Keiichi
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
    Ott, Patrick A.
    Bang, Yung-Jue
    Berton-Rigaud, Dominique
    Elez, Elena
    Pishvaian, Michael J.
    Rugo, Hope S.
    Puzanov, Igor
    Mehnert, Janice M.
    Aung, Kyaw L.
    Lopez, Juanita
    Carrigan, Marion
    Saraf, Sanatan
    Chen, Mei
    Soria, Jean-Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (22) : 2535 - +
12345